Page 50 - 2022_01-Haematologica-web

C.Y. Cheah et al.
Cancer.1983;52(8):1410-1416.
10. Maeshima AM, Taniguchi H, Toyoda K, et
al. Clinicopathological features of histolog- ical transformation from extranodal mar- ginal zone B-cell lymphoma of mucosa- associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174(6):923- 931.
11. Alderuccio JP, Zhao W, Desai A, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018;36(34): 3370-3380.
12. Du MQ. MALT lymphoma: a paradigm of NF-kappaB dysregulation. Semin Cancer Biol. 2016;39:49-60.
13. Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa- associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006;24(19):3136- 3141.
14. Alderuccio JP, Isrow D, Reis IM, et al. Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not? Blood. 2020;135(15):1299-1302.
15. Chae H, Cho H, Sa H-S, et al. The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis. Br J Haematol. 2021;193 (4):848- 851.
16. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409-1417.
17. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) guidelines - B-cell lymphomas 2017 November 15, 2017; version 6.
18. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi144-148.
19. Liu H, Ruskon-Fourmestraux A, Lavergne- Slove A, et al. Resistance of t(11;18) posi- tive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357 (9249):39-40.
20.Ryu KD, Kim GH, Park SO, et al. Treatment outcome for gastric mucosa- associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience. Gut Liver. 2014;8(4):408-414.
21. Ferreri AJ, Cecchetti C, Kiesewetter B, et al. Clarithromycin as a “repurposing drug” against lymphomas: safety and efficacy profiles in 55 patients with extranodal mar- ginal zone lymphoma (EMZL). Hematol Oncol. 2017;35(S2):86-87.
22. Saifi O, Lester SC, Rule W, et al. Comparable efficacy of reduced dose radi- ation therapy for the treatment of early stage gastric extranodal marginal zone lym- phoma of mucosa-associated lymphoid tis- sue. Adv Radiat Oncol. 2021;6(4):100714.
23. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extran- odal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815-3824.
24. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric mar- ginal zone non-Hodgkin's lymphoma
resistant to or not eligible for anti- Helicobacter pylori therapy. J Clin Oncol. 2005;23(9):1979-1983.
25.Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil pro- duces superior event-free survival in the treatment of patients with extranodal mar- ginal-zone B-cell lymphoma: 5-year analy- sis of the IELSG-19 randomized study. J Clin Oncol. 2013;31(5):565-572.
26. Desai A, Joag MG, Lekakis L, et al. Long- term course of patients with primary ocular adnexal MALT lymphoma: a large single- institution cohort study. Blood. 2017;129(3):324-332.
27. Kiesewetter B, Raderer M. Antibiotic thera- py in nongastrointestinal MALT lym- phoma: a review of the literature. Blood. 2013;122(8):1350-1357.
lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2021;39(3): 313-325.
39. Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma. Blood. 2016;127(17): 2064-2071.
40. Pileri S, Ponzoni M. Pathology of nodal marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1):50-55.
41. Conconi A, Franceschetti S, Aprile von Hohenstaufen K, et al. Histologic transfor- mation in marginal zone lymphomas. Ann Oncol. 2015;26(11):2329-2335.
42. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting fea- tures but similar morphologic and pheno- typic profiles. Cancer. 2004; 100(1):107-
28. Ferreri AJ, Ponzoni M, Guidoboni M, et al.
Regression of ocular adnexal lymphoma 115.
after Chlamydia psittaci-eradicating antibi- otic therapy. J Clin Oncol. 2005;23(22): 5067-5073.
29.Teckie S, Qi S, Lovie S, et al. Long-term outcomes and patterns of relapse of early- stage extranodal marginal zone lymphoma treated with radiation therapy with cura- tive intent. Int J Radiat Oncol Biol Phys. 2015;92(1):130-137.
30. MacManus MP, Roos D, O'Brien P, et al. Prospective phase II trial of radiation thera- py in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori sta- tus: TROG 05.02/ALLG NHL15. Eur J Cancer. 2021;152:129-138.
31. de la Fuente MI, Haggiagi A, Moul A, et al. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leuk Lymphoma. 2017;58(4):882-888.
32. Sunderland AJ, Steiner RE, Al Zahrani M, et al. An international multicenter retrospec- tive analysis of patients with extranodal marginal zone lymphoma and histological- ly confirmed central nervous system and dural involvement. Cancer Med. 2020;9(2): 663-670.
33. Jackson AE, Mian M, Kalpadakis C, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41). Oncologist. 2015;20(10): 1149-1153.
34. Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: B-cell lym- phomas, version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650-661.
35.Oh SY, Kim WS, Kim JS, et al. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Commun (Lond). 2019;39(1):58.
36. Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associ- ated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3): e104-111.
37. Alderuccio JP, Beaven AW, Shouse G, et al. Frontline bendamustine and rituximab in extranodal marginal zone lymphoma: an international analysis. Blood. 2020;136 (Suppl 1):2-3.
38. Knauf W, Abenhardt W, Koenigsmann M, et al. Rare lymphomas in routine practice - treatment and outcome in marginal zone
43. van den Brand M, van Krieken JH. Recognizing nodal marginal zone lym- phoma: recent advances and pitfalls. A sys- tematic review. Haematologica. 2013; 98(7):1003-1013.
44. Spina V, Khiabanian H, Messina M, et al. The genetics of nodal marginal zone lym- phoma. Blood. 2016;128(10):1362-1373.
45. Starr AG, Caimi PF, Fu P, et al. Dual institu- tion experience of nodal marginal zone lymphoma reveals excellent long-term out- comes in the rituximab era. Br J Haematol. 2016;175(2):275-280.
46. Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presenta- tion and outcome in 144 patients. Cancer. 2013;119(1):99-106.
47. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119(3):629-638.
48. Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527-2532.
49. Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus- associated marginal zone lymphomas. Leukemia. 2004;18(10):1711-1716.
50. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012;91(4):543-551.
51. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treat- ment for patients with indolent and man- tle-cell lymphomas: an open-label, multi- centre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
52. Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145(6):741-748.
53. Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and ritux- imab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer. 2012; 118(16):3954- 3961.
54.Laribi K, Tempescul A, Ghnaya H, et al.
42
haematologica | 2022; 107(1)